anti-HIgG(Fc)-N-DM1 ADC (CAT#: ADC-AA-008)

A: The anti-HIgG(Fc)-N-DM1 ADC consists of an anti-human IgG Fc specific polyclonal antibody linked to DM1 via a noncleavable linker. DM1 is a cytotoxic molecule that binds to tubulins, disrupting microtubule dynamics and inducing cell death.

A: This ADC is primarily used in research settings to target cells that express Fc receptors, making it useful in studying diseases such as certain cancers where these receptors are overexpressed.

A: In experimental models, this ADC targets tumor cells that express receptors for the Fc portion of human IgG. The specificity of targeting is based on the presence of these receptors, which are often overexpressed in certain tumor types. This allows for selective delivery of the cytotoxic drug, DM1, to tumor cells while sparing normal tissues.

A: Optimal experimental conditions for using the ADC include maintaining physiological pH and temperature during experiments. Researchers should also consider the expression levels of Fc receptors on the target cells to ensure effective binding and internalization of the ADC.

A: The efficacy of this ADC in laboratory settings can be quantified by measuring cell viability assays, apoptosis induction, and cell cycle analysis post-treatment. Additionally, researchers may use imaging techniques to directly observe the disruption of microtubule structures within treated cells.